文献速递核素与放射性配体治疗

225Ac-MACROPATATE:一种用于神经内分泌肿瘤的新型α粒子肽受体放射性核素治疗药物

225Ac-MACROPATATE: A Novel α-Particle Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors.
PubMed 文献 · J Nucl Med · 2022-11-17

本文设计并合成了一种可在室温下螯合225Ac的新型放射性偶联物MACROPATATE,并在体外和体内评估其性能。MACROPATATE对SSTR2的亲和力与DOTATATE相当(解离常数21 nM),225Ac-MACROPATATE在37°C下血清稳定性优于225Ac-DOTATATE。在H69神经内分泌肿瘤小鼠模型中,225Ac-MACROPATATE的肿瘤摄取高于225Ac-DOTATATE,与生理盐水对照相比显示出显著抗肿瘤和生存获益;但225Ac-MACROPATATE在肝脏和肾脏的蓄积增加及由此产生的毒性降低了其治疗指数,作者认为225Ac-DOTATATE是更优的α粒子肽受体放射性核素治疗药物。

要点

  • MACROPATATE可在室温下螯合225Ac,其与SSTR2的亲和力与DOTATATE相当(解离常数21 nM)。
  • 在H69神经内分泌肿瘤小鼠中,225Ac-MACROPATATE的肿瘤摄取高于225Ac-DOTATATE,且较生理盐水对照显示显著抗肿瘤和生存获益。
  • 225Ac-MACROPATATE在肝脏和肾脏的蓄积增加及毒性降低其治疗指数,作者认为225Ac-DOTATATE是更优的α粒子肽受体放射性核素治疗药物。

核心结论

  • 225Ac-MACROPATATE与225Ac-DOTATATE在动物模型中均表现出良好的治疗疗效。
  • 由于225Ac-MACROPATATE的肝脏和肾脏蓄积升高及剂量限制性毒性所需给药活度较低,作者认为225Ac-DOTATATE是靶向α粒子肽受体放射性核素治疗的更优药物。

研究设计与样本

  • 本研究设计并合成了可在室温下螯合225Ac的新型放射性偶联物MACROPATATE,并评估其体外和体内性能。
  • 体外实验使用SSTR2阳性转染细胞系U2-OS-SSTR2评估亲和力及37°C血清稳定性。
  • 体内实验使用皮下H69神经内分泌肿瘤小鼠模型进行生物分布和治疗研究。

主要发现

  • MACROPATATE在U2-OS-SSTR2细胞中与DOTATATE的亲和力相当(解离常数21 nM)。
  • 225Ac-MACROPATATE在37°C下随时间推移的血清稳定性优于225Ac-DOTATATE。
  • 在皮下H69神经内分泌肿瘤小鼠中,225Ac-MACROPATATE的肿瘤摄取高于225Ac-DOTATATE。
  • 在SSTR阳性肿瘤小鼠中,225Ac-MACROPATATE与生理盐水对照相比表现出显著抗肿瘤和生存获益。
  • 225Ac-MACROPATATE在肝脏和肾脏的蓄积增加及对这些器官的后续毒性,降低了其相对于225Ac-DOTATATE的治疗指数。

关键数值与推荐

  • MACROPATATE与DOTATATE在U2-OS-SSTR2细胞中的解离常数为21 nM。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Neuroendocrine tumors (NETs) express somatostatin receptors (SSTRs) 2 and 5. Modified variants of somatostatin, the cognate ligand for SSTR2 and SSTR5, are used in treatment for metastatic and locoregional disease. Peptide receptor radionuclide therapy with 177Lu-DOTATATE (DOTA-octreotate), a β-particle-emitting somatostatin derivative, has demonstrated survival benefit in patients with SSTR-positive NETs. Despite excellent results, a subset of patients has tumors that are resistant to treatment, and alternative agents are needed. Targeted α-particle therapy has been shown to kill tumors that are resistant to targeted β-particle therapy, suggesting that targeted α-particle therapy may offer a promising treatment option for patients with 177Lu-DOTATATE-resistant disease. Although DOTATATE can chelate the clinically relevant α-particle-emitting radionuclide 225Ac, the labeling reaction requires high temperatures, and the resulting radioconjugate has suboptimal stability. Methods: We designed and synthesized MACROPATATE (MACROPA-octreotate), a novel radioconjugate capable of chelating 225Ac at room temperature, and assessed its in vitro and in vivo performance. Results: MACROPATATE demonstrated comparable affinity to DOTATATE (dissociation constant, 21 nM) in U2-OS-SSTR2, a SSTR2-positive transfected cell line. 225Ac-MACROPATATE demonstrated superior serum stability at 37°C over time compared with 225Ac-DOTATATE. Biodistribution studies demonstrated higher tumor uptake of 225Ac-MACROPATATE than of 225Ac-DOTATATE in mice engrafted with subcutaneous H69 NETs. Therapy studies showed that 225Ac-MACROPATATE exhibits significant antitumor and survival benefit compared with saline control in mice engrafted with SSTR-positive tumors. However, the increased accumulation of 225Ac-MACROPATATE in liver and kidneys and subsequent toxicity to these organs decreased its therapeutic index compared with 225Ac-DOTATATE. Conclusion: 225Ac-MACROPATATE and 225Ac-DOTATATE exhibit favorable therapeutic efficacy in animal models. Because of elevated liver and kidney accumulation and lower administered activity for dose-limiting toxicity of 225Ac-MACROPATATE, 225Ac-DOTATATE was deemed the superior agent for targeted α-particle peptide receptor radionuclide therapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. King AP, Gutsche NT, Raju N, et al. 225Ac-MACROPATATE: A Novel α-Particle Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors. J Nucl Med. 2022. PMID: 36396453. doi:10.2967/jnumed.122.264707

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。